AI assistant
Flerie AB — Net Asset Value 2024
Nov 4, 2024
6601_rns_2024-11-04_5728dff9-3d03-4bda-b005-8226fdb17920.pdf
Net Asset Value
Open in viewerOpens in your device viewer
Press Release
04 November 2024 08:00:00 CET
FLERIE
NET ASSET VALUE - 31 October 2024
On the 31 October 2024 Flerie AB's Net Asset Value (NAV) was SEK 4.377 million and NAV per share was SEK 56.06.
| Allocation of NAV | Share of portfolio company | Fair value (MSEK) | Part of NAV per share (SEK) | Share of NAV |
|---|---|---|---|---|
| Product Development | ||||
| Prokarium | 42% | 488 | 6.25 | 11.1% |
| Xspray Pharma | 18% | 351 | 4.50 | 8.0% |
| Empros Pharma | 79% | 204 | 2.62 | 4.7% |
| KAHR Medical | 31% | 202 | 2.59 | 4.6% |
| Atrogi | 37% | 176 | 2.25 | 4.0% |
| Lipum | 57% | 173 | 2.22 | 4.0% |
| Xintela | 56% | 143 | 1.84 | 3.3% |
| Microbiotica | 11% | 139 | 1.78 | 3.2% |
| Mendus | 24% | 123 | 1.57 | 2.8% |
| Geneos Therapeutics | 12% | 103 | 1.31 | 2.3% |
| Toleranzia | 66% | 90 | 1.15 | 2.1% |
| EpiEndo Pharmaceuticals | 9% | 58 | 0.74 | 1.3% |
| Synerkine Pharma | 43% | 53 | 0.68 | 1.2% |
| AnaCardio | 19% | 52 | 0.66 | 1.2% |
| Egetis Therapeutics | 2% | 31 | 0.40 | 0.7% |
| Buzzard Pharmaceuticals | 14% | 29 | 0.37 | 0.7% |
| Vitara Biomedical | 8% | 29 | 0.37 | 0.7% |
| Sixera Pharma | 23% | 26 | 0.33 | 0.6% |
| Alder Therapeutics | 21% | 17 | 0.22 | 0.4% |
| Amarna Therapeutics | 58% | 12 | 0.15 | 0.3% |
| Strike Pharma | 16% | 9 | 0.11 | 0.2% |
| Total | 2.507 | 32.11 | 57.3% | |
| Commercial Growth | ||||
| NorthX Biologics | 92% | 189 | 2.42 | 4.3% |
| Symcel | 31% | 169 | 2.16 | 3.9% |
| Provell Pharmaceuticals | 72% | 75 | 0.96 | 1.7% |
| Chromafora | 31% | 73 | 0.93 | 1.7% |
| Nanologica | 38% | 71 | 0.91 | 1.6% |
| A3P Biomedical | 8% | 42 | 0.54 | 1.0% |
| Frontier Biosolutions | 2% | 19 | 0.25 | 0.4% |
| Bohus Biotech | 45% | 17 | 0.21 | 0.4% |
| Total | 654 | 8.38 | 14.9% | |
| Limited Partnerships, total | 94 | 1.21 | 2.2% | |
| Assets related to Portfolio companies | 316 | 4.05 | 7.2% |
Flerie AB
Skeppsbron 16
111 30 Stockholm
Press Release
04 November 2024 08:00:00 CET
FLERIE
| Other assets and liabilities | 805 | 10.31 | 18.4% | |
|---|---|---|---|---|
| Net asset value | 4.377 | 56.06 | 100.0% | |
- indirect shares in Provell Pharmaceuticals
For more information:
Ted Fjällman, CEO
Email: [email protected]
Flerie in brief
Flerie is an active long-term life science investor, with a broad and diversified portfolio of innovative companies based on pioneering science. We invest in product development and commercial growth opportunities globally alongside other leading investors, focusing predominantly on private companies that are otherwise difficult to access. Flerie's active ownership model, broad network and resources support and accelerate the development of the portfolio projects, creating value for shareholders. Flerie AB's ordinary share is listed on Nasdaq Stockholm with the ticker FLERIE. For further information please visit www.flerie.com
Attachments
NET ASSET VALUE - 31 October 2024
Flerie AB
Skeppsbron 16
111 30 Stockholm